항비만약 시장 : 분자 유형별, 사용 활성 화합물별, 작용기전별, 아고니스트 유형별, 작용 경로별, 투여 경로별, 지역별, 매출 예측, 주요 참가 기업 : 2035년까지의 업계 동향과 세계 예측

Anti-Obesity Drugs Market by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players: Industry Trends and Global Forecasts, till 2035

US $ 4,799 ￦ 6,868,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,016,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,169,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,760,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항비만제 시장 규모는 올해 128억 달러에서 2035년에는 1,049억 달러로 성장할 것으로 예상되며, 예측 기간인 2035년까지 연평균 21.1%의 성장률을 보일 것으로 추정됩니다.

비만은 체지방의 극단적인 축적을 특징으로하는 만성 질환이며 개인에게 심각한 건강 위험을 초래합니다. 세계보건기구(WHO)에 따르면 비만은 세계 사망 원인의 5위를 차지하고 있습니다. 이 신흥국 시장에서의 우려 증가를 억제하기 위해, 현재 다양한 의약품이 시장에서 이용 가능하며, 또한 다양한 개발 단계에 걸쳐 연구되고 있습니다.

체중 감량제라고도 하는 항비만제에는 비만을 관리하고 당뇨병 및 심혈관 장애와 같은 관련 질환을 치료하는 것을 목표로 하는 개인을 돕기 위해 특별히 고안된 여러 의약품 치료가 포함됩니다. 이러한 약물은 식욕 억제, 지방 흡수 억제, 대사율 향상 등 여러 메커니즘을 통해 작용합니다. 적절한 항비만제의 선택은 의료 전문가가 판단하는 것과 같이 병존 질환 및 대사 기능에 대한 잠재적 위험을 고려하면서 각 환자프로파일에 맞추어 이루어집니다. 또한, 신규 화합물의 개발과 약물 제형 및 전달 시스템의 발전으로 더욱 효과적이고 안전한 항비만제가 등장하고 있습니다.

세계 비만률 상승과 당뇨병, 심혈관 질환, 특정 암을 포함한 관련 건강 위험에 대한 의식이 높아짐에 따라 효과적인 항비만제에 대한 수요가 급증하고 있습니다. 게다가 비만의 장기관리가 중시되게 된 것으로, 항비만약 시장은 크게 성장할 전망이며, 향후 수년간 이해 관계자에게 큰 기회를 제공하게 됩니다.

항비만약 시장은 2035년까지 연평균 21.1%(CAGR)로 성장할 것으로 예측되며, 2035년까지 북미가 시장의 대부분의 점유율(-60%)을 차지할 것으로 예측되고 있습니다.

본 보고서에서는 세계의 항비만약 시장에 대해 조사했으며, 시장 개요와 함께 분자유형별, 사용활성화합물별, 작용기전별, 아고니스트유형별, 작용경로별, 투여경로별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 배경

제2장 조사 방법

제3장 시장 역학

제4장 경제 및 기타 프로젝트 특유의 고려 사항

제5장 주요 요약

제6장 소개

제7장 시장 상황 : 항비만약

제8장 기업 프로파일: 북미를 거점으로 하는 항비만약 개발 기업

제9장 기업 프로파일: 유럽을 거점으로 하는 항비만약 개발 기업

제10장 기업 프로파일 : 아시아태평양 및 세계 기타 지역에 본사를 둔 항비만약 개발 기업

제11장 대기업 제약회사의 대처

제12장 시장에 미치는 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제13장 세계의 항비만약 시장

제14장 항비만약 시장, 분자 유형별

제15장 항비만약 시장, 사용 활성 화합물별

제16장 항비만약 시장, 작용기전별

제17장 항비만약 시장, 아고니스트 유형별

제18장 항비만약 시장, 작용 경로별

제19장 항비만약 시장, 투여 경로별

제20장 항비만약 시장, 지역별

제21장 항비만약 시장, 시판약 및 제3상 임상시험약의 매출 예측

• 시판약:매출 예측
• 3상 임상 의약품: 매출 예측

제22장 항비만약 시장, 주요 기업

제23장 부록 1: 표 형식의 데이터

제24장 부록 2 : 기업·단체 일람

SHW

영문 목차

영문목차

ANTI-OBESITY DRUGS MARKET:

As per Roots Analysis, the global anti-obesity drugs market size is estimated to grow from USD 12.8 billion in the current year to USD 104.9 billion by 2035, at a CAGR of 21.1% during the forecast period, till 2035.

The opportunity for anti-obesity drugs market has been distributed across the following segments:

• Type of Molecule
• Biologics
• Small Molecules
• Active Compound Used
• Tirzepatide
• Semaglutide
• Retatrutide
• Survodutide
• Cagrilintide and Semaglutide
• Orforglipron
• Liraglutide
• Other Active Compounds
• Mechanism of Action
• GLP-1 Agonist / GIP Agonist
• GLP-1 Agonist / GCGR Agonist
• GLP-1 Agonist
• GLP-1 Agonist / Amylin Analogue
• GLP-1 / GCGR / GIP Agonist
• Other Mechanisms of Action
• Type of Agonist
• Single-Agonist
• Dual-Agonist
• Tri-Agonist
• Action Pathway
• Centrally Acting
• Peripherally Acting
• Centrally Acting and Peripherally Acting
• Route of Administration
• Oral
• Parenteral
• Geographical Regions
• North America
• Europe
• Asia-Pacific
• Latin America
• Sales Forecast
• Contrave / Mysimba
• Feisumei
• Imcivree
• LOMAIRA
• QSYMIA
• Saxenda
• Wegovy / Ozempic
• Zepbound / Mounjaro
• BI 456906
• CagriSema
• HM11260C
• HRS-9531
• IBI362
• LM-008
• LY3437943
• LY3502970
• TG103
• Semaglutide 7.2 mg (Subcutaneous)
• Semaglutide (Oral)
• XW003
• Key Players

ANTI-OBESITY DRUGS MARKET: GROWTH AND TRENDS

Obesity is a chronic disease, which is characterized by the extreme accumulation of body fat, posing significant health risks to individuals. According to the World Health Organization, obesity is the fifth-leading cause of mortality worldwide. In order to curb this growing concern, various medications are currently available in the market or are being investigated across different phases of development.

Anti-obesity drugs, also referred to as weight loss drugs, include several pharmaceutical treatments designed specifically to assist individuals aiming to manage obesity and treat associated concerns, such as diabetes mellitus and cardiovascular disorders. These drugs work through several mechanisms, including appetite suppression, inhibition of fat absorption, and enhancement of metabolic rate. The selection of appropriate anti-obesity drugs is tailored to each patient's profile, taking into account their co-morbidities and potential risks to metabolic functions, as determined by healthcare professionals. Additionally, the development of novel compounds coupled with ongoing advancements in drug formulation and delivery systems, have led to the emergence of more effective and safer anti-obesity medications.

With rising global obesity rates and increased awareness of the associated health risks including diabetes, cardiovascular diseases, and certain cancers, the demand for effective anti-obesity drugs has surged. Moreover, with a growing emphasis on long-term management of obesity, the anti-obesity drugs market is poised to grow significantly, thus offering significant opportunities to stakeholders in the coming years.

ANTI-OBESITY DRUGS MARKET: KEY INSIGHTS

The report delves into the current state of the anti-obesity market and identifies potential growth opportunities within the industry. The key takeaways of the report are:

1.Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through oral route

2.A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements

3.The growing awareness among patients about the health risks, associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future

4.The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035

5.Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in market by 2035

ANTI-OBESITY DRUGS MARKET: KEY SEGMENTS

Small Molecules is the Fastest Growing Segment of the Anti-obesity Drugs Market

Based on the type of molecule, the global market for anti-obesity is segmented into biologics and small molecules. Currently, the small molecules segment occupies the highest share in the overall market. However, the landscape is likely to evolve as biologics emerge as a promising and more effective alternative that can target the underlying biological pathways associated with obesity.

Semaglutide is Likely to Hold the Largest Share of the Anti-obesity Drugs Market During the Forecast Period

Based on the active compound used, the global market for anti-obesity is segmented into Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide, and other active compounds. Currently, Semaglutide leads the anti-obesity drugs market, and this can be attributed to its strong efficacy in weight management and diabetes control. However, owing to significant research progress, tirzepatide has gained attention for its dual action as both a GLP-1 and GIP receptor agonist, demonstrating superior weight loss results in clinical trials.

Anti-Obesity Drugs Market for GLP-1 agonist is Likely to Grow at a Relatively Faster Pace During the Forecast Period

Based on the mechanism of action, the global market for anti-obesity is segmented across GLP-1 agonist / GIP agonist, GLP-1 agonist / GCGR agonist, GLP-1 agonist, GLP-1 agonist / amylin analogue, GLP-1 / GCGR / GIP agonist and other mechanisms of action. Presently, the market is dominated by GLP-1 agonists, due to their ability to mimic hormone glucagon-like peptide 1 (GLP-1), thereby promoting significant weight loss.

Anti-Obesity Drugs Market for Single Agonist is Likely to Grow at a Higher CAGR During the Forecast Period

Based on the type of agonist, the global market for anti-obesity is segmented into single-agonist, dual-agonist and tri-agonist. Currently, single agonist captures the maximum anti-obesity drugs market share owing to its user-friendliness for facilitating patient adherence.

Anti-Obesity Drugs Catering to Centrally Acting Pathways is Likely to Dominate the Anti-Obesity Drugs Market During the Forecast Period

Based on the action pathway, the global market for anti-obesity is distributed across centrally acting, peripherally acting and, centrally and peripherally acting pathways. Presently, centrally acting segment captures the highest anti-obesity drugs market share and is expected to dominate the market during the forecast period. It is important to note that despite ongoing research into alternative pathways, robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market.

Parenteral Route Hold the Largest Share of the Anti-Obesity Drugs Market

Based on the routes of administration, the global market for anti-obesity is segmented into oral and parenteral. Currently, the parenteral route captures the majority share of the market, owing to its rapid onset of action and higher bioavailability compared to oral formulations.

North America Accounts for the Largest Share of the Market

Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America. In the current scenario, North America is likely to capture the largest market share. This can be attributed to a high prevalence of obesity and related comorbidities, driving the demand for effective treatment options. Additionally, the region benefits from advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks that facilitate the development and approval of new therapies.

Example Players in the Anti-Obesity Drugs Market

• Eli Lilly
• Pfizer
• Regeneron
• Kallyope
• CinFina Pharma
• Viking Therapeutics
• AstraZeneca
• Novo Nordisk
• Roche
• Adocia
• Boehringer Ingelheim
• Zealand Pharma
• Hanmi Pharm
• Jiangsu Hengrui Pharmaceuticals
• Gmax Biopharma
• PegBio
• QL Biopharm
• Sciwind Biosciences

ANTI-OBESITY DRUGS MARKET: RESEARCH COVERAGE

The report on anti-obesity drugs market features insights on various sections, including:

• Market Sizing and Opportunity Analysis: An in-depth analysis of current market opportunity and the future growth potential of anti-obesity drugs market, focusing on key market segments, including [A] type of molecule, [B] active compound used, [C] mechanism of action, [D] type of agonist, [E] action pathway, [F] route of administration, and [G] geographical regions.
• Market Impact Analysis: A thorough analysis of various factors, such as [A] drivers, [B] restraints, [C] opportunities, and [D] existing challenges that are likely to impact market growth.
• Market Landscape: A comprehensive evaluation of companies engaged in anti-obesity domain, based on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] mechanism of action, [D] type of agonist, [E] route of administration, [F] dosage frequency, and [G] type of therapy.
• Anti-obesity Drug Developer Landscape: The report features a list of players engaged in the anti-obesity drug domain, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters, and [D] most active players.
• Company Profiles: In-depth profiles of key industry players in the anti-obesity drug domain, featuring information on [A] company overview, [B] financial information (if available), [C] metaverse in healthcare portfolio, [D] recent developments, and [E] future outlook statements.
• Big Pharma Players: An insightful review of various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters, such as [A] year of initiative, [B] type of initiative, [C] number of partnerships, [D] type of partnership, and [E] type of expansion.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Factors
  • 2.6.1. Demographics
  • 2.6.2. Economic Factors
  • 2.6.3. Competitive Landscape
  • 2.6.4. Government Regulations and Healthcare Policies
  • 2.6.5. R&D Investment
  • 2.6.6. Technological Factors
  • 2.6.7. Industry Consolidation
  • 2.6.8. Supply Chain
  • 2.6.9. Market Access
  • 2.6.10. COVID Impact / Related Factors
  • 2.6.11. Market Access
  • 2.6.12. COVID Impact / Related Factors
  • 2.6.13. Patient Advocacy and Influence
  • 2.6.14. Healthcare Infrastructure

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-Down Approach
  • 3.2.2. Botton-Up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Key Market Segments
• 3.7. Robust Quality Control
• 3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Overview of Major Currencies Affecting the Market
    • 4.2.2.2. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Exchange Impact
    • 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Overview of Anti-Obesity Drugs
• 6.2. Health Risks Linked with Long-term Obesity
• 6.3. Currently Approved Anti-Obesity Drug Classes
• 6.4. Challenges Associated with Anti-Obesity Drugs
• 6.5. Future Perspectives

7. MARKET LANDSCAPE: ANTI-OBESITY DRUGS

• 7.1. Market Landscape: Anti-Obesity Drugs
  • 7.1.1. Analysis by Status of Development
  • 7.1.2. Analysis by Type of Molecule
  • 7.1.3. Analysis by Mechanism of Action
  • 7.1.4. Analysis by Type of Agonist
  • 7.1.5. Analysis by Route of Administration
  • 7.1.6. Analysis by Dosage Frequency
  • 7.1.7. Analysis by Type of Therapy
• 7.2. Developer Landscape: Anti-Obesity Drugs
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Headquarters (Country) and Status of Development
  • 7.2.5. Most Active Developers: Analysis by Number of Drug Candidates

8. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN NORTH AMERICA

• 8.1. Chapter Overview
• 8.2. Detailed Company Profiles
  • 8.2.1. Eli Lilly
    • 8.2.1.1. Company Details
    • 8.2.1.2. Pipeline Portfolio
    • 8.2.1.3. Financial Details
    • 8.2.1.4. Recent Developments and Future Outlook
  • 8.2.2. Pfizer
  • 8.2.3. Regeneron
• 8.3. Brief Company Profiles
  • 8.3.1. CinFina Pharma
    • 8.3.1.1. Company Details
    • 8.3.1.2. Pipeline Portfolio
  • 8.3.2. Kallyope
  • 8.3.3. Viking Therapeutics

9. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN EUROPE

• 9.1. Chapter Overview
• 9.2. Detailed Company Profiles
  • 9.2.1. AstraZeneca
    • 9.2.1.1. Company Details
    • 9.2.1.2. Pipeline Portfolio
    • 9.2.1.3. Financial Details
    • 9.2.1.4. Recent Developments and Future Outlook
  • 9.2.2. Novo Nordisk
  • 9.2.3. Roche
• 9.3. Brief Company Profiles
  • 9.3.1. Adocia
    • 9.3.1.1. Company Details
    • 9.3.1.2. Pipeline Portfolio
  • 9.3.2. Boehringer Ingelheim
  • 9.3.3. Zealand Pharma

10. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

• 10.1. Chapter Overview
• 10.2. Detailed Company Profiles
  • 10.2.1. Hanmi Pharmaceuticals
    • 10.2.1.1. Company Details
    • 10.2.1.2. Pipeline Portfolio
    • 10.2.1.3. Financial Details
    • 10.2.1.4. Recent Developments and Future Outlook
  • 10.2.2. Jiangsu Hengrui Pharmaceuticals
• 10.3. Brief Company Profiles
  • 10.3.1. Gmax Biopharma
    • 10.3.1.1. Company Details
    • 10.3.1.2. Pipeline Portfolio
  • 10.3.2. PegBio
  • 10.3.3. QL Biopharm
  • 10.3.4. Sciwind Biosciences

11. BIG PHARMA INITIATIVES

• 11.1. Methodology
• 11.2. Big Pharma Players: Anti-obesity focused Initiatives
  • 11.2.1. Analysis of Big Pharma Players by Number of Initiatives
  • 11.2.2. Analysis by Year of Initiative
  • 11.2.3. Analysis by Big Pharma Player by Year of Initiative and Number of Initiatives
  • 11.2.4. Analysis by Type of Initiative
  • 11.2.5. Analysis by Year and Type of Initiative
  • 11.2.6. Analysis by Big Pharma Player and Type of Initiative
  • 11.2.7. Analysis by Big Pharma Player and Number of Partnerships
  • 11.2.8. Analysis by Type of Partnership
  • 11.2.9. Analysis by Type of Expansion
  • 11.2.10. Analysis by Big Pharma Player by Region and Number of Initiatives
  • 11.2.11. Benchmarking of Big Pharma Players

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 12.1. Chapter Overview
• 12.2. Market Drivers
• 12.3. Market Restraints
• 12.4. Market Opportunities
• 12.5. Market Challenges

13. GLOBAL ANTI-OBESITY DRUGS MARKET

• 13.1. Forecast Methodology and Key Assumptions
• 13.2. Global Anti-Obesity Drugs Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 13.2.1. Scenario Analysis
    • 13.2.1.1. Conservative Scenario
    • 13.2.1.2. Optimistic Scenario
• 13.3. Key Market Segmentations

14. ANTI-OBESITY DRUGS MARKET, BY TYPE OF MOLECULE

• 14.1. Anti-Obesity Drugs Market: Distribution by Type of Molecule
  • 14.1.1. Anti-Obesity Drugs Market for Biologics, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 14.1.2. Anti-Obesity Drugs Market for Small Molecules, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

15. ANTI-OBESITY DRUGS MARKET, BY ACTIVE COMPOUND USED

• 15.1. Anti-Obesity Drugs Market: Distribution by Active Compound Used
  • 15.1.1. Anti-Obesity Drugs Market for Tirzepatide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.2. Anti-Obesity Drugs Market for Semaglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.3. Anti-Obesity Drugs Market for Retatrutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.4. Anti-Obesity Drugs Market for Survodutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.5. Anti-Obesity Drugs Market for Cagrilintide and Semglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.6. Anti-Obesity Drugs Market for Orforglipron, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.7. Anti-Obesity Drugs Market for Liraglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.1.8. Anti-Obesity Drugs Market for other active compounds used, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

16. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

• 16.1. Anti-Obesity Drugs Market: Distribution by Mechanism of Action
  • 16.1.1. Anti-Obesity Drugs Market for GLP-1 Agonist / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.1.2. Anti-Obesity Drugs Market for GLP-1 Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.1.3. Anti-Obesity Drugs Market for GLP-1 Agonist / GCGR Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.1.4. Anti-Obesity Drugs Market for GLP-1 / GCGR / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.1.5. Anti-Obesity Drugs Market for GLP-1 Agonist / Amylin Analogue, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.1.6. Anti-Obesity Drugs Market for Other Mechanisms of Action, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

17. ANTI-OBESITY DRUGS MARKET, BY TYPE OF AGONIST

• 17.1. Anti-Obesity Drugs Market: Distribution by Type of Agonist
  • 17.1.1. Anti-Obesity Drugs Market for Single-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 17.1.2. Anti-Obesity Drugs Market for Dual-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 17.1.3. Anti-Obesity Drugs Market for Tri-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

18. ANTI-OBESITY DRUGS MARKET, BY ACTION PATHWAY

• 18.1. Anti-Obesity Drugs Market: Distribution by Action Pathway
  • 18.1.1. Anti-Obesity Drugs Market for Centrally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 18.1.2. Anti-Obesity Drugs Market for Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 18.1.3. Anti-Obesity Drugs Market for Centrally Acting and Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

19. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 19.1. Anti-Obesity Drugs Market: Distribution by Route of Administration
  • 19.1.1. Anti-Obesity Drugs Market for Oral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.1.2. Anti-Obesity Drugs Market for Parenteral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

20. ANTI-OBESITY DRUGS MARKET, BY GEOGRAPHICAL REGIONS

• 20.1. Anti-Obesity Drugs Market: Distribution by Geographical Regions
  • 20.1.1. Anti-Obesity Drugs Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 20.1.2. Anti-Obesity Drugs Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 20.1.3. Anti-Obesity Drugs Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 20.1.4. Anti-Obesity Drugs Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21. ANTI-OBESITY DRUGS MARKET, SALES FORECAST OF MARKETED AND PHASE III DRUGS

• 21.1. Marketed Drugs: Sales Forecast
  • 21.1.1. Contrave / Mysimba (Naltrexone, Bupropion)
  • 21.1.2. Feisumei (Beinaglutide)
  • 21.1.3. Imcivree (Setmelanotide)
  • 21.1.4. LOMAIRA (Phentermine Hydrochloride)
  • 21.1.5. QSYMIA (Phentermine and Topiramate)
  • 21.1.6. Saxenda (Liraglutide)
  • 21.1.7. Wegovy / Ozempic (Semaglutide)
  • 21.1.8. Zepbound / Mounjaro (Tirzepatide)
• 21.2. Phase III Drugs: Sales Forecast
  • 21.2.1. BI 456906 (Survodutide)
  • 21.2.2. CagriSema (Cagrilintide and Semaglutide)
  • 21.2.3. HM11260C (Efpeglenatide)
  • 21.2.4. HRS-9531
  • 21.2.5. IBI362 (Mazdutide)
  • 21.2.6. LM-008
  • 21.2.7. LY3437943 (Retatrutide)
  • 21.2.8. LY3502970 (Orforglipron)
  • 21.2.9. TG103
  • 21.2.10. Semaglutide 7.2 mg (Subcutaneous)
  • 21.2.11. Semaglutide (Oral)
  • 21.2.12. XW003

22. ANTI-OBESITY DRUGS MARKET, BY KEY PLAYERS

• 22.1. Anti-Obesity Drugs Market: Distribution of Key Players

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료